Granules India Limited Received ANDA Approval for Sildenafil for Oral Suspension 

December 3, 2023
  • Granules has a total of 63 ANDA approvals from the US FDA (61 final and 2 tentative approvals)
  • Sildenafil for Oral Suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and delay clinical worsening.

India

healthysoch

Hyderabad/Chandigarh, December 03, 2023:

Granules India Limited announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA), filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the company, for Sildenafil for Oral Suspension, 10 mg/mL. It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Revatio for Oral Suspension, 10mg/ml, of Viatris Specialty LLC.

Sildenafil for Oral Suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.

Granules now has a total of 63 ANDA approvals from the US FDA (61 final approvals and 2 tentative approvals). The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million, according to MAT Sep 2023, IQVIA/IMS Health.

healthysoch

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

“Wellness of Brain & Nervous System”

Webinar on Illness to Wellness: Friday, 15th Jan 2021, 11.00 AM

Morning MEDtalks with Dr KK Aggarwal

Morning Health Talk: New Delhi, July 8, 2018: Bombay HC